Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1997

View Archived Issues

Mylan enters distribution agreement for ranitidine

Repligen identifies angiogenic growth factor inhibitors

Merck KGaA discloses novel ET antagonists

RPR prepares novel transfection agents

Ilex Oncology: Q2 1997 highlights

Statins protect against stroke and CVD

InSite Vision: Q2 1997 highlights

Melarsoprol normalizes cytokine levels in human African trypanosomiasis

Roche seeks U.S. and European approval for Corange takeover

Unigene Laboratories and Parke-Davis to develop oral calcitonin for osteoporosis

Papaverine/phentolamine compared to PGE1 for erectile dysfunction

Advantage-24 safe for evaluation in HIV prevention

Picotamide suppresses ACE inhibitor-induced cough

Review of preclinical and clinical studies with xanomeline

SangStat Medical reports encouraging phase III results with Thymoglobulin

Talsaclidine: favorable preclinical and pharmacokinetic profile

Vivus launches new device for erectile dysfunction in the U.S.

Sepracor reports promising phase II results for norastemizole

Antiherpes activity of naturally occurring flavone alone and in combination with aciclovir

Pharmacopeia receives SBIR grant for development of plasmepsin inhibitors

Jenner licenses emulsion formulation from Walter Reed

D-Pharm reports results from toxicity study for neuroprotective compound

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...